ID21411A - Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak - Google Patents

Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak

Info

Publication number
ID21411A
ID21411A IDP981597A ID981597A ID21411A ID 21411 A ID21411 A ID 21411A ID P981597 A IDP981597 A ID P981597A ID 981597 A ID981597 A ID 981597A ID 21411 A ID21411 A ID 21411A
Authority
ID
Indonesia
Prior art keywords
risk
agents
glucose resistance
treat glucose
high damaged
Prior art date
Application number
IDP981597A
Other languages
English (en)
Inventor
Hiroyuki Odaka
Ichiro Nakaoka
Yoshiharu Suzuki
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of ID21411A publication Critical patent/ID21411A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
IDP981597A 1997-12-10 1998-12-08 Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak ID21411A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33968697 1997-12-10

Publications (1)

Publication Number Publication Date
ID21411A true ID21411A (id) 1999-06-10

Family

ID=18329844

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP981597A ID21411A (id) 1997-12-10 1998-12-08 Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak

Country Status (9)

Country Link
US (1) US6200958B1 (id)
EP (1) EP1035854A1 (id)
KR (1) KR100566701B1 (id)
CN (1) CN1142783C (id)
AU (1) AU1505099A (id)
CA (1) CA2314433A1 (id)
ID (1) ID21411A (id)
TW (1) TW589174B (id)
WO (1) WO1999029327A1 (id)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US7067148B2 (en) * 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US7101569B2 (en) * 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030190359A1 (en) * 2001-10-29 2003-10-09 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7108869B2 (en) * 2002-11-07 2006-09-19 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CN101111266A (zh) * 2005-01-31 2008-01-23 味之素株式会社 含有降血糖药的用于改善或治疗糖耐量异常、临界性糖尿病、胰岛素抵抗性和高胰岛素血症的药物组合物
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013081563A2 (en) 2011-10-24 2013-06-06 Mahmut Bilgic Stable tablet formulations
TW201333870A (zh) 2011-12-21 2013-08-16 艾登工具股份有限公司 決定病人胰島素療法的系統及方法
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
MX2018015089A (es) 2016-06-10 2019-05-13 Boehringer Ingelheim Int Combinacion de linagliptina y metformina.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5735303A (en) * 1980-07-30 1982-02-25 Taiyo Yuden Kk Voltage vs current characteristic nonlinear semiconductor porcelain composition and method of producing same
JPS5764648A (en) 1980-10-06 1982-04-19 Takeda Chem Ind Ltd N-substituted derivative of valienamine, its preparation, and alpha-glucosidase inhibitor
EP0056194B1 (en) * 1981-01-05 1984-09-12 Takeda Chemical Industries, Ltd. N-substituted pseudo-aminosugars, their production and use
US4595678A (en) * 1982-03-19 1986-06-17 Takeda Chemical Industries, Ltd. N-substituted pseudo-aminosugars and pharmaceutical compositions containing same

Also Published As

Publication number Publication date
WO1999029327A1 (en) 1999-06-17
KR100566701B1 (ko) 2006-04-03
EP1035854A1 (en) 2000-09-20
CN1142783C (zh) 2004-03-24
CA2314433A1 (en) 1999-06-17
US6200958B1 (en) 2001-03-13
TW589174B (en) 2004-06-01
AU1505099A (en) 1999-06-28
CN1278179A (zh) 2000-12-27
KR20010032906A (ko) 2001-04-25

Similar Documents

Publication Publication Date Title
ID21411A (id) Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak
ID25824A (id) Formulasi terapeutik untuk memberikan tolterodin dengan pelepasan yang terkendali
FI964364A0 (fi) Lyocell-kankaan käsittely fibrilloitumisen vähentämiseksi
ID17156A (id) Zat-zat anti koagulan yang berguna dalam pengobatan trombosis
ID19875A (id) Poliolefin yang dimodifikasi menurut reologi
IS2252B (is) Meðhöndlun á vatni
ID25921A (id) Sulfonamida-sulfonamida untuk pengobatan penyakit-penyakit yang dimediakan endotelin
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE69839259D1 (de) Anordnung von leitungen zum herzen
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
ATE288748T1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69926385D1 (de) Behandlung von geweben
ID20973A (id) Senyawa-senyawa polietilenimina berat molekul rendah yang dapat ditoleransi secara biologi
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
ZA952763B (en) Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
DE60015516D1 (de) Verwendung von makroliden zur behandlung von trockenen augen
ID20819A (id) Semaforin l manusia (h-sema l) dan semaforin yang sesuai dalam spesies lainnya
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
ZA98603B (en) Compositions comprising choline and use of choline to treat endotoxic shock
DE69932235D1 (de) Behandlung von herzhypertrophie
ID19594A (id) Daya tolak permukaan yang dihilangkan
IT1289845B1 (it) Formula per il trattamento della cute e suoi impieghi
DE60012836D1 (de) Verwendung von Simethicone zur Behandlung der ulzerativen Kolitis
DE69806308T2 (de) Behandlung einer Elektrode
GB2353217B (en) Use of ribose to treat fibromyalgia